Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMVY89X)

Drug Name
Cyclo(-L-Am7(S2Py)-D-2MePhe-L-Ala-D-Pro-) Drug Info
Synonyms CHEMBL393261; cyclo(-L-Am7(S2Py)-D-2MePhe-L-Ala-D-Pro-)
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Cross-matching ID
PubChem CID
44437873
TTD Drug ID
DMVY89X

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Patented Agent(s)
Approved Drug(s)
Download the Complete Related Drug List
Drug(s) Targeting Histone deacetylase 6 (HDAC6)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Citarinostat DMQLODU Multiple myeloma 2A83 Phase 1 [2]
KA2507 DMW0H9Y Solid tumour/cancer 2A00-2F9Z Phase 1 [2]
PMID29671355-Compound-62 DMWRS34 N. A. N. A. Patented [3]
PMID29671355-Compound-43 DMVPMWJ N. A. N. A. Patented [3]
PMID29671355-Compound-25 DMPV0KZ N. A. N. A. Patented [3]
PMID29671355-Compound-21 DMPJN0M N. A. N. A. Patented [3]
PMID29671355-Compound-31 DM3H78D N. A. N. A. Patented [3]
PMID29671355-Compound-56 DM0VBMI N. A. N. A. Patented [3]
PMID29671355-Compound-67 DM1RPL4 N. A. N. A. Patented [3]
PMID29671355-Compound-23 DMUBOEX N. A. N. A. Patented [3]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting Histone deacetylase 4 (HDAC4)
Drug Name Drug ID Indication ICD 11 Highest Status REF
PMID29671355-Compound-62 DMWRS34 N. A. N. A. Patented [3]
PMID29671355-Compound-43 DMVPMWJ N. A. N. A. Patented [3]
PMID29671355-Compound-25 DMPV0KZ N. A. N. A. Patented [3]
PMID29671355-Compound-21 DMPJN0M N. A. N. A. Patented [3]
PMID29671355-Compound-31 DM3H78D N. A. N. A. Patented [3]
PMID29671355-Compound-56 DM0VBMI N. A. N. A. Patented [3]
PMID29671355-Compound-67 DM1RPL4 N. A. N. A. Patented [3]
PMID29671355-Compound-23 DMUBOEX N. A. N. A. Patented [3]
PMID29671355-Compound-61 DMXH1G3 N. A. N. A. Patented [3]
PMID29671355-Compound-45a DM5LYKR N. A. N. A. Patented [3]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting Histone deacetylase 1 (HDAC1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Vorinostat DMWMPD4 Adult acute monocytic leukemia Approved [4]
Romidepsin DMT5GNL Cutaneous T-cell lymphoma 2B01 Approved [5]
Panobinostat DM58WKG Chronic graft versus host disease Approved [4]
HBI-8000 DMDWYUN Non-small-cell lung cancer 2C25.Y Registered [6]
ITF2357 DMFZBNE Duchenne dystrophy 8C70 Phase 3 [7]
NVP-LAQ824 DM8JWNA Mood disorder 6A60-6E23 Phase 3 [8]
SNDX-275 DMH7W9X Breast cancer 2C60-2C65 Phase 3 [9]
Phenylbutyrate DMBHPDW Urea cycle disorder 5C50.A Phase 2 [10]
MGCD-0103 DM726HX Non-small-cell lung cancer 2C25.Y Phase 2 [4]
Resminostat DMNE1FR Hepatocellular carcinoma 2C12.02 Phase 2 [11]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Histone deacetylase 1 (HDAC1) TT6R7JZ HDAC1_HUMAN Inhibitor [1]
Histone deacetylase 4 (HDAC4) TTTQGH8 HDAC4_HUMAN Inhibitor [1]
Histone deacetylase 6 (HDAC6) TT5ZKDI HDAC6_HUMAN Inhibitor [1]

References

1 Molecular design of histone deacetylase inhibitors by aromatic ring shifting in chlamydocin framework. Bioorg Med Chem. 2007 Dec 15;15(24):7830-9.
2 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3 HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17.
4 Protein methyltransferases as a target class for drug discovery. Nat Rev Drug Discov. 2009 Sep;8(9):724-32.
5 Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92.
6 Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
7 Emerging drugs for the therapy of primary and post essential thrombocythemia, post polycythemia vera myelofibrosis. Expert Opin Emerg Drugs. 2009 Sep;14(3):471-9.
8 NVP-LAQ824 is a potent novel histone deacetylase inhibitor with significant activity against multiple myeloma. Blood. 2003 Oct 1;102(7):2615-22.
9 Emerging therapies for multiple myeloma. Expert Opin Emerg Drugs. 2009 Mar;14(1):99-127.
10 Emerging disease-modifying therapies for the treatment of motor neuron disease/amyotropic lateral sclerosis. Expert Opin Emerg Drugs. 2007 May;12(2):229-52.
11 2011 Pipeline of 4SC AG.